Media

2019 Press releases

Health Canada Approves Otsuka and Lundbeck's REXULTI® (brexpiprazole) as Adjunctive Treatment of Major Depressive Disorder - February 22, 2019


Members of the media seeking further information may contact:
Catherine Baril
Senior Director, HR and Administration, Human Resources
TEL: 514-894-2777
CBAR@Lundbeck.com

 

You are now leaving www.lundbeck.ca , Lundbeck Canada’s Web site. Links to site outside of Lundbeck Canada are provided as resources to visitors and may not represent Canada regulation or prescribing information. Lundbeck Canada accepts no responsibility in the content of linked sites.